(MedPage Today) — At the International Symposium on Pediatric Neuro-Oncology (ISPNO), investigators reported prospective evidence supporting retreatment with the MEK inhibitor selumetinib (Koselugo) in children with recurrent low-grade glioma…
Source: MedPage Today — Headlines
